Before entering into this agreement Lonza and Solvay already had an ongoing commercial partnership.
As part of the manufacturing alliance Lonza will produce an important selection of Solvay's large volume active pharmaceutical ingredients (API). Traditionally Lonza manufactures chemicals instead of supplying ingredients to be used in products.
Lonza has capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of medicines and healthcare products. Financial terms of the agreement were not disclosed.
“This outsourcing is in line with Solvay Pharmaceuticals strategy of shifting selected manufacturing activities to high quality, competitively-priced alternatives,” said Francesc Junyent, senior vice president of Manufacturing & Supply for Solvay.